Johannes Krisam

Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD

R. Schlenk, M. Kieser, H. Serve, 2023, Trials.

Estimation of treatment effects in early-phase randomized clinical trials involving external control data.

M. Kirchner, Heiko Götte, Armin Schüler, 2023, Journal of biopharmaceutical statistics.

Surgical or non-surgical treatment of plantar fasciopathy (SOFT): study protocol for a randomized controlled trial

R. Schlenk, M. Kieser, H. Serve, 2021, Trials.

“University students’ economic situation during the COVID-19 pandemic: A cross-sectional study in Germany”

J. Krisam, S. C. Gewalt, Sarah Berger, 2022, PloS one.

Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive post-remission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia

R. Schlenk, M. Schaich, C. Schliemann, 2024, Haematologica.